Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM)

Journal of Neuro-Oncology

Volumn 80, Issue 3, 2006, Pages 261-274

  Grunda, Jessica M ^a   Nabors, L Burton ^b   Palmer, Cheryl A ^d   Chhieng, David C ^d   Steg, Adam ^a   Mikkelsen, Tom ^f   Diasio, Robert B ^a   Zhang, Kui ^e   Allison, David ^e   Grizzle, William E ^d   Wang, Wenquan ^e   Gillespie, G Yancey ^c   Johnson, Martin R ^a,e  

^a University of Alabama at Birmingham   (United States)

^b The University of Alabama at Birmingham   (United States)

^c Kentucky   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f HENRY FORD HOSPITAL   (United States)

Author keywords

Glioblastoma multiforme; Glioma; Low density array; Real time quantitative PCR; Ribonucleotide reductase subunit M2; Survival; Survivin; Thymidylate synthetase; Ubiquitin specific protease 10

Indexed keywords

CARMUSTINE; LOMUSTINE; PROCARBAZINE; PROTEINASE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; RNA; SURVIVIN; TAMOXIFEN; TEMOZOLOMIDE; THYMIDYLATE SYNTHASE; UBIQUITIN SPECIFIC PROTEASE 10; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BRAIN RADIATION; BRAIN SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DEMOGRAPHY; EPILEPSY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; POSTOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BRAIN NEOPLASMS; CHILD; DISEASE-FREE SURVIVAL; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; RNA; STATISTICS, NONPARAMETRIC; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 33751242487     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-006-9191-4     Document Type: Article

References (58)

1. McLendon RE, Halperin EC (2003) Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 98(8):1745-1748
2. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA (2001) Malignant glioma: Genetics and biology of a grave matter. Genes Dev 15(11):1311-1333
3. Fazeny-Dorner B, Gyries A, Rossler K, Ungersbock K, Czech T, Budinsky A, Killer M, Dieckmann K, Piribauer M, Baumgartner G, Prayer D, Veitl M, Muhm M, Marosi C (2003) Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center. Wien Klin Wochenschr 115(11):389-397
4. Zhou YH, Tan F, Hess KR, Yung WK (2003) The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: Relationship to tumor grade and survival. Clin Cancer Res 9(9):3369-3375
5. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20(4):1063-1068
6. Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF (2003) Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22(31):4918-4923
7. van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, Sommer C, Reifenberger G, Hanash SM (2003) Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163(3):1033-1043
8. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63(7):1602-1607
9. Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, Bruner JM, Zhang W (2002) Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 12(1):108-116
10. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, Kononen J (2000) Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60(23):6617-6622
11. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB, Aldape KD (2002) Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 8(1):180-187
12. Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88(1):1-10
13. Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C (2005) Glioblastoma multiforme with long term survival. Neurol India 53(3):329-332
14. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P (1999) Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46(2):183-188
15. Senger D, Cairncross JG, Forsyth PA (2003) Long-term survivors of glioblastoma: Statistical aberration or important unrecognized molecular subtype? Cancer J 9(3):214-221
16. Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, Marsault C, Philippon J, Klatzmann D (2002) Long-term survival after gene therapy for a recurrent glioblastoma. Neurology 58(7):1109-1112
17. Blanquicett C, Johnson MR, Heslin M, Diasio RB (2002) Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem 303(2):209-214
18. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB (2000) Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 278(2):175-184
19. Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE, Johnson MR (2006) Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn 8(1):76-83
20. Harrington DP, Felming TR (1982) A class of rand test procedures for censored survival data. Biometrika 69:553-566
21. Lee CK, Allison DB, Brand J, Weindruch R, Prolla TA (2002) Transcriptional profiles associated with aging and middle age-onset caloric restriction in mouse hearts. Proc Natl Acad Sci USA 99(23):14988-14993
22. Zar JH (1999) Biostatistical analysis, 4th ed. Prentice-Hall, Upper Saddle River
23. Allison DB, Gadbury G, Heo M, Fernandez J, Lee C, Prolla TA, Weindruch R (2002) A mixture model approach for the analysis of microarray gene expression data. Comput Stat Data Anal (39):1-20
24. Hatfield GW, Hung SP, Baldi P (2003) Differential analysis of DNA microarray gene expression data. Mol Microbiol 47(4):871-877
25. Klecka WR (1980) Discriminant analysis. Sage University Paper Series on Quantitative Applications in the Social Sciences Series No. 07-019
26. Fisher RA (1936) The use of multiple measurements in taxonomic problems. Ann Eugenic (7):179-188
27. Ambroise C, McLachlan GJ (2002) Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci USA 99(10):6562-6566
28. Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis. Neuro-oncology 6(3):227-235
29. Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22(53):8581-8589
30. Yamamoto T, Tanigawa N (2001) The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsci 34(4):207-212
31. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K (2003) Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97(4):1077-1083
32. Zaffaroni N, Pennati M, Daidone MG (2005) Survivin as a target for new anticancer interventions. J Cell Mol Med 9(2):360-372
33. Fulda S, Debatin KM (2004) Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 23(40):6702-6711
34. Zhang T, Fields JZ, Ehrlich SM, Boman BM (2004) The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 308(2):434-437
35. Chu E, Callender MA, Farrell MP, Schmitz JC (2003) Thymidylate synthase inhibitors as anticancer agents: From bench to bedside. Cancer Chemother Pharmacol 52(Suppl 1):S80-S89
36. Saga Y, Suzuki M, Mizukami H, Urabe M, Fukushima M, Ozawa K, Sato I (2002) Enhanced expression of thymidylate synthase mediates resistance of uterine cervical cancer cells to radiation. Oncology 63(2):185-191
37. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, Inoue M, Tatematsu M (1998) A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82(1):70-77
38. Nomura T, Nakagawa M, Fujita Y, Hanada T, Mimata H, Nomura Y (2002) Clinical significance of thymidylate synthase expression in bladder cancer. Int J Urol 9(7):368-376
39. Suzuki M, Ohwada M, Tamada T, Tsuru S (1994) Thymidylate synthase activity as a prognostic factor in ovarian cancer. Oncology 51(4):334-338
40. Menei P, Capelle L, Guyotat J, Fuentes S, Assaker R, Bataille B, Francois P, Dorwling-Carter D, Paquis P, Bauchet L, Parker F, Sabatier J, Faisant N, Benoit JP (2005) Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: A randomized phase II trial. Neurosurgery 56(2):242-248 (discussion 242-248)
41. Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL (2001) Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 24(4):421-424
42. Blanquicett C, Buchsbaum DJ, Saif MW, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR (2005) Antitumor efficacy of capecitabine and celecoxib in irradiated and lead shielded contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects in a metastatic model. Clin Cancer Res (submitted)
43. Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR (2002) Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther 1(12):1139-1145
44. Newman AJ, Fiveash J, Rosenfeld S, Johnson M, Diasio R, Wang W, Cockrell-Donohue A, Nabors LB (2004) A phase I study of capecitabine, concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM). In: Grunberg SM, Gary A, Whippen D (eds) Proc Am Soc Clin Oncol, New Orleans LA, June 5-8 2004. Lisa Greaves, American Society of Clinical Oncology, Alexandria, 2004, 116 pp
45. Benepal TS, Judson I (2005) ZD9331: Discovery to clinical development. Anticancer Drugs 16(1):1-9
46. Roos-Mattjus P, Sistonen L (2004) The ubiquitin-proteasome pathway. Ann Med 36(4):285-295
47. Amerik AY, Hochstrasser M (2004) Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 1695(1-3):189-207
48. Doelling JH, Yan N, Kurepa J, Walker J, Vierstra RD (2001) The ubiquitin-specific protease UBP14 is essential for early embryo development in Arabidopsis thaliana. Plant J 27(5):393-405
49. Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, Bernards R (2005) The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 17(3):331-339
50. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, Gu W (2002) Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416(6881): 648-653
51. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M (2004) The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5(3):253-261
52. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9(17):6316-6325
53. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23(3):630-639
54. Burton TR, Kashour T, Wright JA, Amara FM (2003) Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: MRNA stabilization, drug resistance, and malignancy (Review). Int J Oncol 22(1):21-31
55. Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A (2003) GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 63(11):2802-2811
56. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23(8): 1539-1548
57. Jung CP, Motwani MV, Schwartz GK (2001) Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7(8):2527-2536
58. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn M, Brandes AA, Cairncross JG, Lacombe D, Mirimanoff RO (2004) Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trail by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. In: Grunberg SM, Gary A, Whippen D (eds) Proc Am Soc Clin Oncol, New Orleans, Louisiana, June 5-8 2004. Lisa Greaves, American Society of Clinical Oncology, Alexandria, 2004, p 1